Posted in | News | Nanomedicine

NanoViricides CEO to Provide Update on Drug Programs at LD Micro Invitational Conference

NanoViricides, Inc. (the “Company”) reports that its CEO, Dr. Eugene Seymour, MD, MPH, will be presenting at the LD Micro Invitational Conference today at 5pm Pacific Time at the Luxe Sunset Boulevard Hotel in West Los Angeles.

Dr. Seymour will provide an update on the Company’s drug programs, and the cGMP clinical product manufacturing facility.

This facility in Shelton, CT, is nearing completion of the construction phase and is entering the facility validation phase. The fully customizable manufacturing facility will enable cGMP manufacture of all of our nanoviricides® drug candidates in kilogram scale, sufficient for pre-IND and human clinical studies.

The Company intends to begin the safety/toxicology studies of its Injectable FluCide™ drug candidate as soon as feasible. The Company is in the process of producing sufficient drug substance for these studies at its existing facility. This injectable FluCide drug candidate is intended to treat hospitalized patients with influenza. It is designed to be broad-spectrum, and thus is expected to work against most, if not all, forms of influenza virus, including epidemic, pandemic (e.g. H1N1/2009), high path influenzas such as H3N2, H7N9, and “bird flu” such as H5N1. This drug candidate has demonstrated an unparalleled 1,000-fold reduction in lung viral load in a lethal animal model study. In the same study, the current standard of care, oseltamivir, (Tamiflu®, Roche) exhibited only a 2-fold reduction in lung viral load at the same time point.

The Company is working on five additional commercially important drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral FluCide™ for out-patients, and a broad-spectrum antiviral drug for viral diseases of the external eye. All of our programs are for therapeutics to treat viral infections. Our drugs are expected to be useful as prophylactics as well.

DengueCide has recently received orphan drug designation by the US FDA as well as the European EMA.

NanoViricides recently received an important international award, the “IAIR Award 2014 for Leadership in Nanomedicines in the North American Sector”.

The market size for our first drug, injectable FluCide, for use in hospitalized patients with influenza, is estimated to be in excess of a billion dollars. There is no satisfactory treatment available for this indication at present. In addition, the overall influenza market is expected to be in several billions of dollars. The total market size addressed by the Company’s current drug programs is estimated at about $40 billion or more.

The Company currently has approximately $36.6 million cash-in-hand and cash-like-instruments. These funds are estimated to be sufficient for taking at least one of our drug candidates through initial human clinical trials, and possibly take another drug candidate into human clinical trials.

Dr. Seymour’s presentation will be made available on our website (www.nanoviricides.com).

About LD Micro:

is LD Micro is a newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. LD Micro concentrates on finding, researching, and investing in companies that are often overlooked by institutional investors. It is a non-registered investment advisor. For more information or to register for the event, please visit www.ldmicro.com or call (408) 457-1042.

About NanoViricides:

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Source: http://www.nanoviricides.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 11). NanoViricides CEO to Provide Update on Drug Programs at LD Micro Invitational Conference. AZoNano. Retrieved on March 02, 2024 from https://www.azonano.com/news.aspx?newsID=30306.

  • MLA

    NanoViricides, Inc. "NanoViricides CEO to Provide Update on Drug Programs at LD Micro Invitational Conference". AZoNano. 02 March 2024. <https://www.azonano.com/news.aspx?newsID=30306>.

  • Chicago

    NanoViricides, Inc. "NanoViricides CEO to Provide Update on Drug Programs at LD Micro Invitational Conference". AZoNano. https://www.azonano.com/news.aspx?newsID=30306. (accessed March 02, 2024).

  • Harvard

    NanoViricides, Inc. 2019. NanoViricides CEO to Provide Update on Drug Programs at LD Micro Invitational Conference. AZoNano, viewed 02 March 2024, https://www.azonano.com/news.aspx?newsID=30306.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.